Causal inference methods are gaining increasing prominence in pharmaceutical drug development in light of the recently published addendum on estimands and sensitivity analysis in clinical trials to the E9 guideline of the International Council for Harmonisation. The E9 addendum emphasises the need to account for post-randomization or `intercurrent' events that can potentially influence the interpretation of a treatment effect estimate at a trial's conclusion. Instrumental Variables (IV) methods have been used extensively in economics, epidemiology and academic clinical studies for `causal inference', but less so in the pharmaceutical industry setting until now. In this tutorial paper we review the basic tools for causal inference, including graphical diagrams and potential outcomes, as well as several conceptual frameworks that an IV analysis can sit within. We discuss in detail how to map these approaches to the Treatment Policy, Principal Stratum and Hypothetical `estimand strategies' introduced in the E9 addendum, and provide details of their implementation using standard regression models. Specific attention is given to discussing the assumptions each estimation strategy relies on in order to be consistent, the extent to which they can be empirically tested and sensitivity analyses in which specific assumptions can be relaxed. We finish by applying the methods described to simulated data closely matching two recent pharmaceutical trials to further motivate and clarify the ideas
翻译:鉴于最近出版的《国际协调理事会E9准则》临床试验中的估计值和敏感性分析增编以及临床试验中的灵敏度分析,病因推断方法在药物开发中越来越突出。E9增编强调,需要说明可能影响到对试验结论中治疗效果估计解释的自发性或“内流”事件;在经济学、流行病学和学术临床研究中广泛使用“因果推断”的工具变量(四)方法,但制药业迄今较少如此。在本指导文件中,我们审查了因果关系推断的基本工具,包括图表和潜在结果,以及四类分析可以包含的若干概念框架。我们详细讨论了如何将这些方法描述为E9增编中引入的治疗效应估计值、主要斯特拉图和Hypothetic `战略',并使用标准回归模型详细介绍其实施情况。具体注意讨论每项估计战略的假设,以便保持一致,在多大程度上可以将具体检验结果的敏感度转化为我们进行模拟分析的方法。